Drug Profile
Research programme: herpes simplex virus protease inhibitors - Agouron/Japan Tobacco
Latest Information Update: 22 Sep 2006
Price :
$50
*
At a glance
- Originator Agouron Pharmaceuticals
- Developer Agouron Pharmaceuticals; Japan Tobacco
- Class
- Mechanism of Action Herpes simplex virus protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Herpes simplex virus infections
Most Recent Events
- 22 Sep 2006 Discontinued - Preclinical for Herpes simplex virus infections in USA (unspecified route)
- 22 Jun 2000 Warner-Lambert has merged with Pfizer
- 24 May 1999 Agouron acquired by Warner-Lambert